atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
Company profile
Ticker
LIFE
Exchange
Website
CEO
Sanjay Shukla
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
LIFE stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
5 Apr 24
DEFA14A
Additional proxy soliciting materials
5 Apr 24
DEF 14A
Definitive proxy
5 Apr 24
10-K
2023 FY
Annual report
14 Mar 24
8-K
Results of Operations and Financial Condition
14 Mar 24
EFFECT
Notice of effectiveness
21 Nov 23
CORRESP
Correspondence with SEC
16 Nov 23
UPLOAD
Letter from SEC
15 Nov 23
S-3
Shelf registration
9 Nov 23
424B5
Prospectus supplement for primary offering
9 Nov 23
Transcripts
LIFE
Earnings call transcript
2023 Q4
14 Mar 24
LIFE
Earnings call transcript
2022 Q4
9 Mar 23
LIFE
Earnings call transcript
2022 Q3
11 Nov 22
LIFE
Earnings call transcript
2022 Q2
16 Aug 22
LIFE
Earnings call transcript
2022 Q1
10 May 22
LIFE
Earnings call transcript
2021 Q4
15 Mar 22
LIFE
Earnings call transcript
2021 Q3
11 Nov 21
LIFE
Earnings call transcript
2021 Q2
11 Aug 21
LIFE
Earnings call transcript
2021 Q1
14 May 21
LIFE
Earnings call transcript
2020 Q4
24 Mar 21
Latest ownership filings
SC 13G/A
LYTTON LAURENCE W
14 Feb 24
SC 13G/A
Stonepine Capital Management, LLC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Sanjay Shukla
6 Feb 24
4
Jill Marie Broadfoot
6 Feb 24
4
NANCY DENYES
6 Feb 24
SC 13G/A
FEDERATED HERMES, INC.
18 Jan 24
4
Sanjay Shukla
9 Jan 24
4
Jill Marie Broadfoot
9 Jan 24
4
NANCY DENYES
9 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 13.24 mm | 13.24 mm | 13.24 mm | 13.24 mm | 13.24 mm | 13.24 mm |
Cash burn (monthly) | 831.33 k | 613.33 k | 4.21 mm | 3.91 mm | 3.19 mm | 2.71 mm |
Cash used (since last report) | 5.65 mm | 4.17 mm | 28.56 mm | 26.55 mm | 21.64 mm | 18.41 mm |
Cash remaining | 7.59 mm | 9.07 mm | -15.32 mm | -13.31 mm | -8.40 mm | -5.17 mm |
Runway (months of cash) | 9.1 | 14.8 | -3.6 | -3.4 | -2.6 | -1.9 |
Institutional ownership, Q3 2023
62.0% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 47 |
Opened positions | 10 |
Closed positions | 9 |
Increased positions | 6 |
Reduced positions | 17 |
13F shares | Current |
---|---|
Total value | 57.15 bn |
Total shares | 42.12 mm |
Total puts | 3.50 k |
Total calls | 18.50 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
FHI Federated Hermes Inc - Ordinary Shares | 10.17 mm | $16.07 bn |
FMR | 8.56 mm | $13.52 bn |
Stonepine Capital Management | 4.63 mm | $7.31 bn |
Tikvah Management | 2.46 mm | $3.89 bn |
Alyeska Investment | 2.46 mm | $3.88 bn |
Vanguard | 2.28 mm | $3.61 bn |
Citadel Advisors | 1.78 mm | $2.82 bn |
Alta Partners VIII | 1.59 mm | $11.04 mm |
BLK Blackrock | 1.36 mm | $2.14 bn |
Aspire Capital Fund | 1.31 mm | $8.18 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
6 Feb 24 | Broadfoot Jill Marie | Common stock | Sell | Dispose S | No | No | 1.69 | 1,590 | 2.69 k | 20,821 |
5 Feb 24 | Denyes Nancy | Common stock | Option exercise | Acquire M | No | No | 0 | 2,688 | 0.00 | 14,767 |
5 Feb 24 | Denyes Nancy | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 2,688 | 0.00 | 5,374 |
5 Feb 24 | Broadfoot Jill Marie | Common stock | Option exercise | Acquire M | No | No | 0 | 3,750 | 0.00 | 22,411 |
5 Feb 24 | Broadfoot Jill Marie | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 3,750 | 0.00 | 7,500 |
5 Feb 24 | Shukla Sanjay | Common stock | Option exercise | Acquire M | No | No | 0 | 10,375 | 0.00 | 116,548 |
5 Feb 24 | Shukla Sanjay | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 10,375 | 0.00 | 20,750 |
5 Jan 24 | Denyes Nancy | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 150,000 | 225.00 k | 150,000 |
5 Jan 24 | Broadfoot Jill Marie | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 1.5 | 150,000 | 225.00 k | 150,000 |
News
12 Health Care Stocks Moving In Tuesday's After-Market Session
9 Apr 24
RBC Capital Maintains Outperform on aTyr Pharma, Lowers Price Target to $16
15 Mar 24
HC Wainwright & Co. Reiterates Buy on aTyr Pharma, Maintains $35 Price Target
15 Mar 24
Recap: aTyr Pharma Q4 Earnings
14 Mar 24
aTyr Pharma Q4 2023 GAAP EPS $(0.25) Misses $(0.24) Estimate
14 Mar 24